摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2E)-3-[4-(3-phenylpropoxy)phenyl]but-2-enal | 847584-66-1

中文名称
——
中文别名
——
英文名称
(2E)-3-[4-(3-phenylpropoxy)phenyl]but-2-enal
英文别名
(E)-3-[4-(3-phenylpropoxy)phenyl]but-2-enal
(2E)-3-[4-(3-phenylpropoxy)phenyl]but-2-enal化学式
CAS
847584-66-1
化学式
C19H20O2
mdl
——
分子量
280.367
InChiKey
BKPXBUKXOKHTLX-DTQAZKPQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    455.1±24.0 °C(Predicted)
  • 密度:
    1.056±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    21
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2E)-3-[4-(3-phenylpropoxy)phenyl]but-2-enal 在 sodium tetrahydroborate 、 sodium hydroxide 、 原甲酸三甲酯 作用下, 以 四氢呋喃甲醇 为溶剂, 生成 trans-3-(3-(4-(3-Phenylpropoxy)phenyl)but-2-enylamino)propanoic acid
    参考文献:
    名称:
    Structure–activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety
    摘要:
    Structure-activity relationship of sphingosine-1-phosphate receptor agonist was examined. In terms of reducing the flexibility of molecule, hit compound 1 was modified to improve S1P(1) agonistic activity as well as selectivity over S1P(3) agonistic activity. Novel S1P agonists with cinnamyl scaffold or 1,2,5,6-tetrahydropyridine scaffold were identified. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.01.029
  • 作为产物:
    描述:
    3-(4-hydroxyphenyl)but-2-enenitrile 在 二异丁基氢化铝potassium carbonate 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 生成 (2E)-3-[4-(3-phenylpropoxy)phenyl]but-2-enal
    参考文献:
    名称:
    Structure–activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety
    摘要:
    Structure-activity relationship of sphingosine-1-phosphate receptor agonist was examined. In terms of reducing the flexibility of molecule, hit compound 1 was modified to improve S1P(1) agonistic activity as well as selectivity over S1P(3) agonistic activity. Novel S1P agonists with cinnamyl scaffold or 1,2,5,6-tetrahydropyridine scaffold were identified. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.01.029
点击查看最新优质反应信息

文献信息

  • Compound capable of binding s1p receptor and pharmaceutical use thereof
    申请人:Nakade Shinji
    公开号:US20070167425A1
    公开(公告)日:2007-07-19
    A compound having an ability to bind to an S 1 P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like. wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R 1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R 1 is a substituent, and wherein m is 2 or more, R 1 s are the same or different.
    一种具有结合S1P受体的能力的化合物(特别是EDG-6,最好是EDG-1和EDG-6),例如本发明的式(I)所表示的化合物,其盐,溶剂合物或前药,对于预防和/或治疗移植排斥,移植物抗宿主病,自身免疫性疾病,过敏性疾病等是有用的。其中,环A是一个环状基团;环B是一个可能具有取代基的环状基团;X是具有1至8个原子的主链的间隔物等;Y是具有1至10个原子的主链的间隔物等;n为0或1,其中当n为0时,m为1且R1是氢原子或取代基,当n为1时,m为0或1至7的整数且R1是取代基,当m为2或更多时,R1相同或不同。
  • Compound capable of binding S1P receptor and pharmaceutical use thereof
    申请人:Nakade Shinji
    公开号:US08791159B2
    公开(公告)日:2014-07-29
    A compound having an ability to bind to an SIP receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
    具有结合SIP受体能力的化合物,其化学式表示为(I),其盐,溶剂化物或前药,对于预防和/或治疗移植排斥、移植物抗宿主病、自身免疫性疾病、过敏性疾病等具有用处:其中环A是一个环状基团;环B是一个环状基团,可能带有取代基;X是具有1到8个原子的主链的间隔物等;Y是具有1到10个原子的主链的间隔物等;n为0或1,当n为0时,m为1且R1为氢原子或取代基,当n为1时,m为0或1到7的整数且R1为取代基,当m为2或更多时,R1相同或不同。
  • COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:EP1661881B1
    公开(公告)日:2014-12-17
  • US7825109B2
    申请人:——
    公开号:US7825109B2
    公开(公告)日:2010-11-02
  • US8791159B2
    申请人:——
    公开号:US8791159B2
    公开(公告)日:2014-07-29
查看更多